Federal Judge Won’t Alter Dismissal Of GLP-1 Compounding Pharmacy’s Antitrust Case
SAN ANTONIO — A Texas federal judge left intact the dismissal with prejudice of a compounding pharmacy’s antitrust claims against the manufacturers of glucagon-like peptide-1…
DO
By Daniel Okafor · Regulatory Correspondent
Nov 3 09:58 ETSource: Mealey's
From the source
Read at mealeys.comFederal Judge Won’t Alter Dismissal Of GLP-1 Compounding Pharmacy’s Antitrust Case
SAN ANTONIO — A Texas federal judge left intact the dismissal with prejudice of a compounding pharmacy’s antitrust claims against the manufacturers of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications approved by the U.S. Food and Drug Administration, finding no manifest legal error in her conclusion that the pharmacy’s compounded GLP-1 drugs were not meaningful market alternatives t
